

Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2018

<https://marketpublishers.com/r/C5928A74BCFEN.html>

Date: October 2018

Pages: 289

Price: US\$ 2,950.00 (Single User License)

ID: C5928A74BCFEN

Abstracts

This report can be delivered to the clients within 24 hours

'Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2018', report provides comprehensive Insight about marketed and pipeline drugs across this Immunotherapy. The report provides the detailed analysis of 190+ products along with 60+ companies involved. Celgene Corporation and bluebird bio has been granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for bb2121 Anti-BCMA CAR-T Cell Therapy for Relapsed and Refractory Multiple Myeloma.

Products covered by Phase

Phase II, Phase I and IND

Pre-clinical and Discovery

Overview of pipeline development activities for Chimeric Antigen Receptor (CAR) T cell Immunotherapy

Pipeline analysis of 190+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.

Therapeutic segmentation of products for Chimeric Antigen Receptor (CAR) T cell Immunotherapy

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.

METHODOLOGY

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SCOPE

The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy

The report provides the marketed drugs information including its sales, development activities and details of patent expiry

The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy

The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling

Pipeline products coverage based on various stages of development ranging from mid stage till discovery stages

Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

REASONS TO BUY

Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

Establish a comprehensive understanding of the current pipeline scenario across Chimeric Antigen Receptor (CAR) T cell Immunotherapy to formulate effective R&D strategies

Assess challenges and opportunities that influence Chimeric Antigen Receptor (CAR) T cell Immunotherapy R&D

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

Devise corrective measures for pipeline projects by understanding Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline depth and focus of Indication therapeutics

Developing strategic initiatives to support your drug development activities

Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Chimeric Antigen Receptor (CAR) T cell Immunotherapy to enhance and expand business potential and scope

Provides strategically significant competitor information, analysis, and Insight to formulate effective R&D development strategies

Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs

Gaining a full picture of the Competitive Landscape for Evidence based Decisions

Contents

- Overview
- Chimeric antigen receptor (CAR) T-cells
- History
- CARs and Generations
- Advantages of CAR-T cells
- Adverse Events with CAR T-cell Therapy
- Limitations of Existing Technologies for CAR T-Cells
- Marketed Products
- Kymriah: Novartis
- Product Description
- Regulatory Milestones
- Research and Development
- Other Clinical Activities
- Product Development Activities
- Pipeline Therapeutics
- Clinical Phase Products
- Non-Clinical Phase Products
- Competitive Landscape
- Comparative Analysis
- Mid Stage Products (Phase II)
- Comparative Analysis
- AU105: Aurora BioPharma
- Product Description
- Research and Development
- Product Development Activities
- (The list continues)
- Early Stage Products (Phase I)
- Comparative Analysis
- IND Stage Products
- Comparative Analysis
- Unknown Stage Products
- Comparative Analysis
- Pre-clinical and Discovery Products
- Comparative Analysis
- Therapeutic Assessment: Clinical Phase Products
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration

Appendix

List Of Tables

LIST OF TABLES

Table 1: CARs Generations

Table 2: CARs Generations-Associated Target Antigens and Indications

Table 3: Total Products for CART Cell therapy

Table 4: Mid Stage Products (Phase II)

Table 5: Early Stage Products (Phase I)

Table 6: IND Stage Products

Table 7: Unknown Stage Products

Table 8: Pre-clinical Stage Products

Table 9: Discovery Stage Products

Table 10: Assessment by Route of Administration

Table 11:: Assessment by Stage and Route of Administration

List Of Figures

LIST OF FIGURES

- Figure 1: Total Products for CART Cell therapy
- Figure 2: Mid Stage Products (Phase II)
- Figure 3: Early Stage Products (Phase I)
- Figure 4: IND Stage Products
- Figure 5: Unknown Stage Products
- Figure 6: Pre-clinical and Discovery Stage Products
- Figure 7: Assessment by Route of Administration
- Figure 8: Assessment by Stage and Route of Administration

I would like to order

Product name: Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2018

Product link: <https://marketpublishers.com/r/C5928A74BCFEN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5928A74BCFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

